hologic discovery w dexa machine  (Hologic Inc)

Journal: Frontiers in Pharmacology

Article Title: Osteoprotective Effects in Postmenopausal Osteoporosis Rat Model: Oral Tocotrienol vs. Intraosseous Injection of Tocotrienol-Poly Lactic-Co-Glycolic Acid Combination

doi: 10.3389/fphar.2021.706747

Figure Lengend Snippet: DEXA Parameters (pre- and posttreatment). (A) Bone mineral content of the tibial bone. (B) Bone mineral density of the tibial bone. SHAM, sham-operated group; OVX, ovariectomized control group; OVX + ESTO, ovariectomized + oral estrogen; OVX + TTO, ovariectomized + daily oral tocotrienol; OVX + TTL, ovariectomized + IO injection of tocotrienol + PLGA. *Significant difference ( p < 0.05) when compared before and after treatment. a Significant difference ( p < 0.05) when compared with the ovariectomized control group (OVX). The data were expressed as mean + SEM.

Article Snippet: Prior to the scanning procedure, a Hologic Discovery W DEXA machine (Hologic, Inc., MA, United States) was calibrated using “Small Animal Phantom.” The DEXA analysis was performed using the APEX TM software.

Techniques: Control, Injection

Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants

doi: 10.1210/jc.2018-01922

Figure Lengend Snippet: Comparison of regional body fat (by DEXA scan) of children with FPLD2 to the NHANES controls. Filled symbols signify subjects with typical LMNA mutations, and unfilled symbols indicate those with atypical LMNA mutations in females (circles) and males (squares). Longitudinal data of two patients are shown connected with a solid line, with the green and red triangles indicating the onset of thelarche and menarche, respectively. The data from the NHANES controls have been drawn as age-specific percentile values for comparison. (A) The upper limb fat is <25th percentile in all affected females, with a downward trend after 12 years. The female with a typical LMNA mutation and longitudinal data over a period of 7 years (filled circles connected with a line) has downtrending upper limb fat even before thelarche, but the female with atypical LMNA mutation and longitudinal data over a period of 3 years (unfilled circles connected with a line) has not had considerable fat loss even after menarche. (B) The upper limb fat ranges between the 1st and 25th percentile in affected males. (C) All affected females, except one with atypical FPLD2, had lower limb fat at or below the first percentile after 8 years of age. The female with typical LMNA mutation and longitudinal data had lower limb fat below the first percentile ∼1.5 years before thelarche, but the female with atypical LMNA mutation and longitudinal data has not had marked fat loss even after menarche. (D) Two males with typical FPLD2 had lower limb fat <5th percentile of NHANES, and the two with atypical FPLD2 were <25th percentile. (E) Truncal fat ranged between the 1st and 75th percentile in most females with no specific trends. Longitudinal data on two females showed downtrending truncal fat. (F) The truncal fat ranged between the 1st and 50th percentile in the affected males.

Article Snippet: Whole-body, trunk, upper limb, and lower limb fat mass measurements were obtained by DEXA scan using Discovery W (S/N 80502) model machine (Hologic Inc., Bedford, MA) in children 8 to 18 years of age.

Techniques: Comparison, Mutagenesis